FDA Accepts Ready-to-Use Bivalirudin NDA for Filing

The FDA has accepted for filing the New Drug Application (NDA) for ready-to-use (RTU) bivalirudin (Eagle) for the treatment of patients undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIa inhibitor; undergoing PCI with, or at risk of heparin-induced thrombocytopenia and thrombosis syndrome; or with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).

The Fittest City in the U.S. Is…

Washington, D.C, is the fittest of the 50 largest cities in the United States, according to the eighth annual American Fitness Index (AFI) rankings from the American College of Sports Medicine and the Anthem Foundation.